Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Other Operating Expenses (2016 - 2026)

United Therapeutics' Other Operating Expenses history spans 17 years, with the latest figure at $103.4 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 36.23% to $103.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $384.4 million, a 24.12% increase, with the full-year FY2025 number at $384.4 million, up 24.12% from a year prior.
  • Other Operating Expenses hit $103.4 million in Q4 2025 for United Therapeutics, up from $100.9 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for UTHR hit a ceiling of $140.2 million in Q1 2021 and a floor of $25.9 million in Q1 2022.
  • Historically, Other Operating Expenses has averaged $67.1 million across 5 years, with a median of $70.6 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: plummeted 82.12% in 2021 and later soared 115.82% in 2023.
  • Tracing UTHR's Other Operating Expenses over 5 years: stood at $34.6 million in 2021, then skyrocketed by 69.94% to $58.8 million in 2022, then grew by 20.75% to $71.0 million in 2023, then rose by 6.9% to $75.9 million in 2024, then soared by 36.23% to $103.4 million in 2025.
  • Business Quant data shows Other Operating Expenses for UTHR at $103.4 million in Q4 2025, $100.9 million in Q3 2025, and $87.6 million in Q2 2025.